ArticlePLoS medicine2020
Isoniazid-resistant tuberculosis: A problem we can no longer ignore.
Article in PLoS medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Real-world treatment outcomes of a 6-month fluoroquinolone-containing regimen for isoniazid mono-resistant pulmonary tuberculosis in Korea.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Rates and risk factors of monoresistance against isoniazid and multidrug-resistant tuberculosis in Almaty, Kazakhstan.BMC infectious diseases · 2026Article
- Peptide-Based Strategies AgainstPharmaceuticals (Basel, Switzerland) · 2025Review
- Factors associated with unfavourable treatment outcomes among patients with Multidrug-resistant Tuberculosis receiving outpatients care.Scientific reports · 2025Article
- Sudapyridine (WX-081) inhibitsmSphere · 2025Article
- Drug resistance profile of Mycobacterium tuberculosis complex isolated from pulmonary tuberculosis patients and their household contacts in central Ethiopia.BMC infectious diseases · 2025Article
- Article
- Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.Antimicrobial agents and chemotherapy · 2024Article
- The Hidden Epidemic of Isoniazid-Resistant Tuberculosis in South Africa.Annals of the American Thoracic Society · 2024Article
- Drug resistance profiles ofJAC-antimicrobial resistance · 2024Article
- Article
- Monitoring of First-line Drug Resistance Mutations Outside the Scope of Xpert MTB/RIF Ultra is Needed for Successful Control of DR-TB in Southern Mozambique.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Extrapulmonary tuberculosis in Africa: Molecular analysis of clinical specimens of suspected cases in Northern Ghana.Public health challenges · 2024Article
- Evaluation of mycobacteria infection prevalence and optimization of the identification process in North Sardinia, Italy.Microbiology spectrum · 2024Article
- Spatial pattern of isoniazid-resistant tuberculosis and its associated factors among a population with migrants in China: a retrospective population-based study.Frontiers in public health · 2024Article
- New Application ofMolecules (Basel, Switzerland) · 2023Article
- Pulmonary Tuberculosis in Children: A Forgotten Disease?Microorganisms · 2023Review
- Dimethyl itaconate is effective in host-directed antimicrobial responses against mycobacterial infections through multifaceted innate immune pathways.Cell & bioscience · 2023Article
- Phylogeography and transmission of Mycobacterium tuberculosis spanning prisons and surrounding communities in Paraguay.Nature communications · 2023Article
- First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giorgia Sulis and Madhukar Pai discuss the global distribution, and approaches to diagnosis and treatment, of isoniazid-resistant tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.